May 15, 2018
Agilvax, Inc., a biotechnology company that develops targeted cancer immunotherapies and vaccines, has completed a Series A1 financing, which complements the Series A round from 2014. Both Series A and A1 were led by Hunt Holdings with a co-investment by Sun Mountain Capital. The funds will be used to expand the pre-IND studies for its lead program AX09 in triple negative breast cancer (TNBC).
May 01, 2018
Agilvax, Inc., a biotechnology company developing novel cancer immunotherapies and vaccines, announced today that it is now a resident company at Johnson & Johnson Innovation, JLABS (JLABS @ TMC) at the renowned Texas Medical Center—the world’s largest cancer center—located in Houston, TX .
Agilvax to Attend J.P. Morgan Healthcare Conference, Biotech Showcase™ 2018 & RESI San Francisco 2018
January 04, 2018
Agilvax Inc., a biotechnology company that develops targeted cancer immunotherapies and vaccines, announced today that its management team Dr. Federica Pericle (President & CEO) and Les Stewart (COO) will be attending J.P. Morgan Healthcare Conference, Biotech Showcase™ 2018 and RESI San Francisco 2018.
New Scientific Publication Supports Agilvax’s Novel Immunotherapy Development for Metastatic Breast Cancer
December 05, 2017
Agilvax, Inc. announced a significant milestone for its immunotherapy, AX09, for the treatment of triple negative breast cancer (TNBC).
September 22, 2017
Federica Pericle, President & CEO, will be attending the 10th Annual BioPharm America Conference in Boston, MA, September 26-27, 2017.
April 06, 2017
Federica Pericle, PhD, MBA President and CEO of Agilvax was accepted into the 2017 Pharma class of the Springboard Health Innovation Hub.
March 31, 2017
Agilvax, Inc., announced today that Dr. John O’Rourke, Director of Oncology, will be presenting a poster, AX09: An Immunotherapy Candidate Targeting the Breast Cancer Stem Cell Protein xCT, at the American Association for Cancer Research (AACR) Annual Meeting to be held in Washington, DC, April 1-5, 2017.
November 17, 2016
Agilvax, Inc., today announced that it has been awarded a subcontract from Leidos valued at approximately $400,000 for the screening and development of a potential epitope-based malaria vaccine candidate.
September 14, 2016
Agilvax, Inc. today announced that Faith L. Charles, partner in Thompson Hine‘s Corporate Transactions & Securities practice group and chair of the firm’s Life Sciences group, has been elected to Agilvax’s board of directors, effective September 13, 2016.
September 06th, 2016
Agilvax, Inc. a leader in the discovery and development of vaccines and cancer immunotherapies is pleased to announce the Notice of Allowance by the U.S. Patent and Trademark office on August 26, 2016 of a new patent related to the company’s human papillomavirus (HPV) vaccine candidate.
Agilvax Appoints Dr. Brad Vale Former Head of Johnson & Johnson Development Corporation (JJDC) to its Board Of Directors
July 20th, 2016
Agilvax, Inc. today announced it has appointed Brad Vale, PhD, DVM to its Board of Directors. Dr. Vale is an expert corporate executive in the biotechnology, pharmaceutical and medical device investing arena. His appointment was effective July 20th 2016.
July 6th, 2016
National Institute of Allergy and Infectious Diseases (NIAID) has awarded Agilvax a one-year, $286,000 grant under the Small Business Innovation Research (SBIR) program entitled “Development of a VLP-based RSV vaccine targeting pre-fusion F protein.”
Agilvax Receives Notice of Allowance for U.S. and European Patents Covering its Vaccine and Cancer Immunotherapy Discovery and Development Platform Technology
February 29th, 2016
Agilvax, Inc. is pleased to announce that it has recently received a Notice of Allowance in United States Patent Application serial number 13/520,057 and an Intention to Grant in European Patent Application 10841780.9 entitled, “Plasmids and Methods for Peptide Display and Affinity-Selection on Virus-Like Particles of RNA Bacteriophages”.
Agilvax to Attend The 34th Annual J.P. Morgan Healthcare Conference and the 8th Annual Biotech Showcase Conference
January 8, 2016
Agilvax Inc., announced today that Dr. Federica Pericle, President & CEO, and Michael Perrine, Director of Business Development will be representing Agilvax during the 34th Annual J.P. Morgan Healthcare Conference and the 8th Annual Biotech Showcase Conference in San Francisco, CA January 11-14, 2016.
Agilvax announces Strategic Collaboration with Integrated BioTherapeutics to Develop a Novel Pan-Ebola Vaccine
July 20, 2015
Agilvax, Inc. today announced a collaboration with Integrated BioTherapeutics (IBT), a leader in filovirus and other emerging infectious disease research, to develop novel vaccines against filoviruses such as Ebola and Marburg.
Agilvax to Collaborate With Sandia National Laboratories & NMSBA To Develop Vaccines And Immunotherapies That Lack Cold-chain Requirements
May 12, 2015
Agilvax, Inc. announced an agreement with Sandia National Laboratories to optimize the long-term stability and efficacy of the Company’s products.
Agilvax To Present At The 2015 Annual Conference On Vaccine Research and Attend The 7th Annual ChinaBio Partnering Forum
April 8, 2015
Agilvax Inc., a biotechnology company that develops vaccines and immunotherapies to combat infectious diseases and cancer, announced today that Dr. Mitchell Tyler, Director of Research & Development, will be presenting a poster at the 2015 Annual Conference on Vaccine Research in Bethesda, MD April 13-15, 2015.
March 18, 2015
Agilvax Inc., a biotechnology company that develops vaccines and immunotherapies to combat infectious diseases and cancer, announced today that that President & CEO, Federica Pericle, will attend the 12th Annual Bio Asia International Conference in Tokyo, Japan, March 24-25, 2015.
Agilvax Announces Strategic Collaboration with Humabs BioMed SA to Develop Targeted Vaccines and Immunotherapies
February 17, 2015
Agilvax, Inc. today announced a collaboration with Switzerland based Humabs BioMed that will contribute to the rapid advancement of Agilvax’s ever expanding vaccine and immunotherapy pipeline.
February 03, 2015
Albuquerque, NM (February 03, 2015) - Agilvax, Inc. announced an agreement with the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) to expedite the clinical development of Agilvax’s virus-like-particle (VLP) vaccine targeting human papillomavirus (HPV).
January 5, 2015
Agilvax Inc. announced today that Michael Perrine, MS, MBA, Director of Business Development will be representing the company at the 7th Annual Biotech Showcase™ in San Francisco January 12-14, 2015. Agilvax welcomes the opportunity to discuss its first-in-class immunotherapy and vaccine discovery and development platform.
Agilvax President and CEO, Federica Pericle, tied for first place at the RMVCA2014: ABQ Pitch Unplugged
August 28, 2014
On Thursday August 28, 2014 Agilvax President and CEO, Federica Pericle, tied for first place at the Rocky Mountain Venture Capital Association 2014 ABQ Pitch Unplugged event at Albuquerque’s Marble Brewery.